文献速递妇科产科

局部晚期宫颈癌治疗后鳞状细胞癌抗原作为生存预后因素:西班牙多中心研究

Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
PubMed 文献 · Gynecol Oncol · 2021-06-10

本研究为西班牙多中心回顾性研究,纳入2000至2016年8家参考医院收治的447例局部晚期宫颈癌患者(FIGO 2009分期IB2、IIA2-IVA),评估治疗后血浆鳞状细胞癌抗原(SCC-Ag)水平作为独立生存预后因素的临床价值。中位随访53个月,多因素Cox回归显示治疗后SCC-Ag≥1.2 ng/ml是总生存的独立危险因素(HR 1.95;95%CI 1.11-3.44;p=0.02)。

要点

  • 治疗后SCC-Ag≥1.2 ng/ml是局部晚期宫颈癌总生存的独立危险因素。
  • 腹主动脉旁淋巴结受累、FIGO分期晚期、治疗反应不完全亦为独立预后因素。
  • 治疗后SCC-Ag cutoff为1.24 ng/ml(敏感性34.6%;特异性83.1%)。

核心结论

  • 治疗后血浆SCC-Ag水平≥1.2 ng/ml是局部晚期宫颈癌患者生存的独立危险因素。
  • 影响生存的其他因素包括腹主动脉旁淋巴结受累、疾病晚期和同步放化疗反应差。

研究设计与样本

  • 回顾性多中心研究,纳入2000至2016年西班牙8家参考医院妇科肿瘤单元管理的局部晚期宫颈癌患者(FIGO 2009分期IB2、IIA2-IVA)。
  • 共纳入447例患者,中位随访53个月(IQR 26-101)。
  • 采用ROC曲线确定治疗后SCC-Ag预测生存的cutoff值,Kaplan-Meier法计算生存曲线,log-rank检验比较,Cox模型分析预后因素。

主要发现

  • 中位治疗前SCC-Ag为3.4 ng/ml(IQR 1.2-11),中位治疗后SCC-Ag为0.8 ng/ml(IQR 0.5-1.2)。
  • 治疗前SCC-Ag cutoff为11.75 ng/ml(敏感性37.5%;特异性80.5%),治疗后SCC-Ag cutoff为1.24 ng/ml(敏感性34.6%;特异性83.1%)。
  • 多因素Cox回归中总生存的独立预测因素包括:FIGO分期(HR 2.12;95%CI 1.18-3.8;p=0.011)、腹主动脉旁淋巴结受累(HR 3.56;95%CI 2.04-6.2;p<0.0001)、治疗后SCC-Ag≥1.2 ng/ml(HR 1.95;95%CI 1.11-3.44;p=0.02)和治疗反应不完全(HR 4.5;95%CI 2.5-8.11;p<0.0001)。

关键数值与推荐

  • 治疗后SCC-Ag≥1.2 ng/ml为总生存独立危险因素(HR 1.95;95%CI 1.11-3.44;p=0.02)。
  • 治疗后SCC-Ag cutoff为1.24 ng/ml(敏感性34.6%;特异性83.1%)。
  • 治疗前SCC-Ag cutoff为11.75 ng/ml(敏感性37.5%;特异性80.5%)。

临床怎么用

  • 对于局部晚期宫颈癌患者,治疗后检测血浆SCC-Ag水平有助于生存预后分层。
  • 治疗后SCC-Ag≥1.2 ng/ml提示生存风险增高,可考虑加强随访或进一步干预。

局限性

  • 本研究为回顾性多中心研究。
  • 治疗后SCC-Ag cutoff的敏感性较低(34.6%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the clinical value of postreatment plasmatic levels of the squamous cell carcinoma antigen (SCC-Ag) as a survival independent prognostic factor in patients with LACC. METHODS: Retrospective, multicenter study including LACC patients (FIGO 2009 stages IB2, IIA2-IVA) managed at the Gynecology Oncological Units corresponding to eight reference hospitals in Spain between 2000 and 2016. Receiver operating characteristic (ROC) curve analysis was used to determine the cut-off values of postreatment SCC-Ag levels in prediction of survival. Survival curves were calculated by using the Kaplan-Meier method and were compared with the log-rank test. Cox models were used to analyze different factors in terms of their prognosis predictive value. RESULTS: The study included 447 patients with a median follow-up time of 53 months (IQR 26-101) and median pre- and postreatment SCC-Ag levels of 3.4 ng/ml (IQR 1.2-11) and 0.8 ng/ml (IQR 0.5-1.2), respectively. The cut-off level of pretreatment SCC-Ag was 11.75 ng/ml (sensibility 37.5%; specificity 80.5%) and that of postreatment SCC-Ag was 1.24 ng/ml (sensibility 34.6%; specificity 83.1%). In a multivariate Cox regression analysis, factors that were independent predictors of OS were: FIGO stage (HR 2.12; 95%CI 1.18-3.8; p = 0.011), paraaortic lymph node involvement (HR 3.56; 95%CI 2.04-6.2; p < 0.0001), postreatment SCC-Ag level ≥ 1.2 ng/ml (HR 1.95; 95%CI 1.11-3.44; p = 0.02) and incomplete response to treatment (HR 4.5; 95%CI 2.5-8.11; p < 0.0001). CONCLUSION: Postreatment plasmatic SCC-Ag level ≥ 1.2 ng/ml was an independent risk factor for the survival of patients with LACC. Further factors influencing survival included: paraaortic lymph node involvement, advanced disease and poor response to concomitant chemoradiotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Benito V, Lubrano A, Pérez-Regadera JF, et al. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group. Gynecol Oncol. 2021. PMID: 34119366. doi:10.1016/j.ygyno.2021.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。